Deals Of The Week: Will Pharmasset’s Windfall Lead To Similar Exits For Other Hepatitis C Biotechs?
Almost two weeks later, people are still talking about ramifications from Gilead’s $11 billion buyout of Pharmasset, but companies such as Roche, Elan and Curis have been active deal makers in recent days.
You may also be interested in...
Curis Teams Up With LLS To Fund Early-Stage Research
Lexington, Mass-based Curis landed up to $4 million in funding from The Leukemia & Lymphoma Society to help develop its preclinical treatment for B-cell lymphoma and multiple myeloma.
Curis/Genentech Report Positive Phase II Results For Vismodegib
Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.
Pharma’s Digital Pathology Build-Out; Part 2 – What It Means
Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.